Opus Genetics, Retained Earnings vs. Total Debt
| IRD Stock | 1.01 0.03 3.06% |
Retained Earnings | First Reported 2010-12-31 | Previous Quarter -81.5 M | Current Value -85.5 M | Quarterly Volatility 22.8 M |
For Opus Genetics, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Opus Genetics, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Opus Genetics, utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Opus Genetics,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Opus Genetics, over time as well as its relative position and ranking within its peers.
Opus |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Opus Genetics, Total Debt vs. Retained Earnings Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Opus Genetics,'s current stock value. Our valuation model uses many indicators to compare Opus Genetics, value to that of its competitors to determine the firm's financial worth. Opus Genetics, is currently regarded as number one stock in retained earnings category among its peers. It also is considered the number one company in total debt category among its peers . At present, Opus Genetics,'s Retained Earnings are projected to decrease significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Opus Genetics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Opus Total Debt vs. Retained Earnings
Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Opus Genetics, |
| = | (81.47 M) |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Opus Genetics, |
| = | 4.04 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Opus Total Debt vs Competition
Opus Genetics, is considered the number one company in total debt category among its peers. Total debt of Biotechnology industry is currently estimated at about 230.31 Million. Opus Genetics, claims roughly 4.04 Million in total debt contributing just under 2% to stocks in Biotechnology industry.
Opus Genetics, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Opus Genetics,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Opus Genetics, will eventually generate negative long term returns. The profitability progress is the general direction of Opus Genetics,'s change in net profit over the period of time. It can combine multiple indicators of Opus Genetics,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -1.3 M | -1.4 M | |
| Operating Income | -10.6 M | -11.1 M | |
| Net Loss | -10 M | -10.5 M | |
| Income Before Tax | -10 M | -10.5 M | |
| Total Other Income Expense Net | 1.9 M | 2 M | |
| Net Loss | -10 M | -10.5 M |
Opus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Opus Genetics,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Opus Genetics, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Opus Genetics,'s important profitability drivers and their relationship over time.
| Retained Earnings vs Revenue | ||
| Net Income vs Total Debt | ||
| Retained Earnings vs Cash Flow From Operations | ||
| Number Of Employees vs Total Debt | ||
| Retained Earnings vs Total Asset | ||
| Working Capital vs Total Debt |
Use Opus Genetics, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Opus Genetics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Opus Genetics, will appreciate offsetting losses from the drop in the long position's value.Opus Genetics, Pair Trading
Opus Genetics, Pair Trading Analysis
The ability to find closely correlated positions to Opus Genetics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Opus Genetics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Opus Genetics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Opus Genetics, to buy it.
The correlation of Opus Genetics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Opus Genetics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Opus Genetics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Opus Genetics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Opus Genetics, position
In addition to having Opus Genetics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
To fully project Opus Genetics,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Opus Genetics, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Opus Genetics,'s income statement, its balance sheet, and the statement of cash flows.